<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02319239</url>
  </required_header>
  <id_info>
    <org_study_id>ETL R14009</org_study_id>
    <secondary_id>R14009</secondary_id>
    <nct_id>NCT02319239</nct_id>
  </id_info>
  <brief_title>Prostate Cancer Stereotactic Radiotherapy</brief_title>
  <acronym>ESKO</acronym>
  <official_title>Development of Prostate Cancer Stereotactic Radiotherapy in Tampere Using Intra-fractional Movement Detector and Diffusion-weighted Magnetic Resonance Imaging.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary purpose of the study is to develop a stereotactic radiation treatment (RT) to&#xD;
      prostate cancer which minimizes treatment related toxicity. Movement of the prostate during a&#xD;
      radiation therapy will be monitored by temporary implanted electromagnetic transmitter. This&#xD;
      data will be used to define prostate marginals (PTV) for stereotactic treatment. Radiation&#xD;
      toxicity to rectum will be reduced by using a rectum fixation during a treatment.&#xD;
&#xD;
      Study group I (20 patients) will be treated 39 x 2 Gy and study group II (20 patients) with&#xD;
      20 x 3 Gy fractionation schedules. With the data collected from these groups treatment&#xD;
      marginals to prostate will be defined and used to treat group III (40 patients) with 5 x 7.25&#xD;
      Gy.&#xD;
&#xD;
      Second purpose of this study is to assess if Diffusion-weighted magnetic resonance imaging&#xD;
      could be used to evaluate radiation treatment response in intermediate prostate cancer.&#xD;
      Androgen deprivation therapy is not allowed in this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      New local prostate cancer patients needing external radiotherapy are included into three&#xD;
      radiation dose groups;&#xD;
&#xD;
      Group I will be treated normal dosing (39 x 2 Gy) and study group II with hypofractionated&#xD;
      dosing (20 x 3 Gy) and group III extreme hypofractionated dosing. Primary goal is to develop&#xD;
      safe and effective curative radiotherapy for these patients&#xD;
&#xD;
      Second aim is to study Diffusion-weighted magnetic resonance image (DW MRI) in radiation&#xD;
      treatment response in intermediate prostate cancer.&#xD;
&#xD;
      Patients are followed by MRI, PSA, bone scans and quality of life questionaries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">October 2020</completion_date>
  <primary_completion_date type="Actual">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine whether the temporary implanted electromagnetic transmitter could be used to reduce treatment marginals in prostate cancer radiation therapy</measure>
    <time_frame>1 to 3 months</time_frame>
    <description>Prostate specific antigen (PSA) recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of DW-MRI to predict the outcome of prostate cancer radiation therapy</measure>
    <time_frame>0 - 12 months</time_frame>
    <description>PSA recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life changes</measure>
    <time_frame>1 to 3 months</time_frame>
    <description>questionaires</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Prostate Neoplasms</condition>
  <condition>Toxicity Due to Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Conventional fractionation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypofractionated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic fractionation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Fractionation</intervention_name>
    <description>During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.</description>
    <arm_group_label>Conventional fractionation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofractionated</intervention_name>
    <description>During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months</description>
    <arm_group_label>hypofractionated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic fractionation</intervention_name>
    <description>During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months</description>
    <arm_group_label>Stereotactic fractionation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy-proven prostate Cancer&#xD;
&#xD;
          -  One or two risk factors for intermediate prostate cancer:&#xD;
&#xD;
               -  Gleason score 7&#xD;
&#xD;
               -  T2b-T2c&#xD;
&#xD;
               -  PSA 10-20 microg/l&#xD;
&#xD;
          -  No need for androgen deprivation therapy&#xD;
&#xD;
          -  Eligible fo MRI&#xD;
&#xD;
          -  Radical radiotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Locally advanced or metastatic prostate cancer&#xD;
&#xD;
          -  Previous radiotherapy to pelvic reason&#xD;
&#xD;
          -  Other severe disease&#xD;
&#xD;
          -  Previous cancer within 5 years&#xD;
&#xD;
          -  Severe urinary symptoms at the start of the study (over 20)&#xD;
&#xD;
          -  Wide cavity after transurethral resection of prostate (TURP)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petri Reinikainen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere Unviersity Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>December 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2014</study_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate neoplasms</keyword>
  <keyword>Urogenital neoplasms</keyword>
  <keyword>Genital neoplasms, male</keyword>
  <keyword>Radiation therapy</keyword>
  <keyword>Prostate specific antigen</keyword>
  <keyword>DW-MRI, diffusion weighted MRI</keyword>
  <keyword>Intra-fractional movement</keyword>
  <keyword>Hypofractionated radiotherapy</keyword>
  <keyword>Stereotactic</keyword>
  <keyword>Toxicity due to radiotherapy</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

